Literature DB >> 12172907

Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies.

Kensuke Sasaki1, Katsumi Doh-ura, Yoshinobu Wakisaka, Toru Iwaki.   

Abstract

Clusterin/apolipoprotein J protein expression in cases with "alpha-synucleinopathies", such as Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA), was investigated using an immunohistochemical method for the labeling of multiple antigens. About 50% of the cortical Lewy bodies in the cases with DLB were immunoreactive for clusterin, whereas brain-stem Lewy bodies in PD and DLB were rarely associated with clusterin. Clusterin was also immunopositive in around 10% of the glial cytoplasmic inclusions (GCIs) in the cases with MSA. Colocalization of clusterin with alpha-synuclein in such bodies or inclusions was clearly correlated with the immunostaining pattern of alpha-synuclein. Subcellular localization of clusterin was almost completely overlapped with the homogeneous immunoreaction of alpha-synuclein in the cortical Lewy bodies; however, clusterin immunoreactivity was not detected in the halo or ring-like structures of the brain-stem Lewy bodies. Furthermore, some Lewy bodies with intense immunoreactivity for clusterin showed only a weak signal for alpha-synuclein. These results suggest that clusterin may modify the formation of alpha-synuclein-positive inclusion bodies such as Lewy bodies and GCIs, through a previously proposed chaperone property of clusterin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12172907     DOI: 10.1007/s00401-002-0546-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  21 in total

Review 1.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

2.  CSF markers of neurodegeneration in Parkinson's disease.

Authors:  Hana Přikrylová Vranová; Jan Mareš; Martin Nevrlý; David Stejskal; Jana Zapletalová; Petr Hluštík; Petr Kaňovský
Journal:  J Neural Transm (Vienna)       Date:  2010-08-21       Impact factor: 3.575

3.  The chaperone protein clusterin may serve as a cerebrospinal fluid biomarker for chronic spinal cord disorders in the dog.

Authors:  Intan N F Shafie; Mark McLaughlin; Richard Burchmore; Mary Ann A Lim; Paul Montague; Pamela E J Johnston; Jacques Penderis; Thomas J Anderson
Journal:  Cell Stress Chaperones       Date:  2013-08-29       Impact factor: 3.667

4.  Gene expression correlates of neurofibrillary tangles in Alzheimer's disease.

Authors:  Travis Dunckley; Thomas G Beach; Keri E Ramsey; Andrew Grover; Diego Mastroeni; Douglas G Walker; Bonnie J LaFleur; Keith D Coon; Kevin M Brown; Richard Caselli; Walter Kukull; Roger Higdon; Daniel McKeel; John C Morris; Christine Hulette; Donald Schmechel; Eric M Reiman; Joseph Rogers; Dietrich A Stephan
Journal:  Neurobiol Aging       Date:  2005-10-19       Impact factor: 4.673

5.  Association of apolipoprotein J-positive beta-amyloid plaques with dystrophic neurites in Alzheimer's disease brain.

Authors:  M D Martin-Rehrmann; H-S Hoe; E M Capuani; G W Rebeck
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

6.  The neural chaperone proSAAS blocks α-synuclein fibrillation and neurotoxicity.

Authors:  Timothy S Jarvela; Hoa A Lam; Michael Helwig; Nikolai Lorenzen; Daniel E Otzen; Pamela J McLean; Nigel T Maidment; Iris Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

7.  Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects.

Authors:  Chera L Maarouf; Thomas G Beach; Charles H Adler; Holly A Shill; Marwan N Sabbagh; Terence Wu; Douglas G Walker; Tyler A Kokjohn; Alex E Roher
Journal:  Neurol Res       Date:  2012-09       Impact factor: 2.448

8.  Structural characterization of clusterin-chaperone client protein complexes.

Authors:  Amy R Wyatt; Justin J Yerbury; Mark R Wilson
Journal:  J Biol Chem       Date:  2009-06-17       Impact factor: 5.157

9.  An exploratory study on CLU, CR1 and PICALM and Parkinson disease.

Authors:  Jianjun Gao; Xuemei Huang; Yikyung Park; Albert Hollenbeck; Honglei Chen
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

10.  Intracellular fibril formation, calcification, and enrichment of chaperones, cytoskeletal, and intermediate filament proteins in the adult hippocampus CA1 following neonatal exposure to the nonprotein amino acid BMAA.

Authors:  Oskar Karlsson; Anna-Lena Berg; Jörg Hanrieder; Gunnel Arnerup; Anna-Karin Lindström; Eva B Brittebo
Journal:  Arch Toxicol       Date:  2014-05-06       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.